FCA

Almost exactly 25 years ago, in 1986, Senator Charles Grassley and Representative Howard Berman led efforts in Congress to amend the False Claims Act, including enhancements to the qui tam provisions to encourage whistleblowers to come forward with allegations of fraud.   (That almost certainly was not the last time there was bipartisan agreement in Congress on a major issue, though we cannot vouch for this with complete certainty.)

Oracle Corp. and Oracle America Inc.

Guidant LLC, a wholly owned subsidiary of Boston Scientific Corp.

TriWest Healthcare Alliance Corporation, a contractor to TRICARE Management Activity, has agreed to pay $10 million to resolve civil false claims allegations, the Justice Department announced today.  TRICARE is the U.S. medical benefit plan which covers uniformed personnel, retirees, their dependents and reserve components. 

The U.S. has partially intervened in a lawsuit under the False Claims Act against Halifax Hospital Medical Center and Halifax Staffing Inc. in the U.S. District Court for the Middle District of Florida.   

The U.S. Court of Appeals for the First Circuit has reinstated claims under a number of state False Claims Acts against Amgen Inc. 

Joseph Ubaghs, a licensed clinical social worker, has entered into a civil settlement with the federal and state governments in which he will pay $210,000 to resolve allegations that he violated the False Claims Act. 

Armor Group North America Inc. (AGNA) and its affiliates have paid the United States $7.5 million to resolve allegations that AGNA submitted false claims for payment on a State Department contract to provide armed guard services at the U.S. Embassy in Kabul, Afghanistan. The settlement resolves U.S.

Federal prosecutors have filed a complaint under the False Claims Act (FCA) against Bay Area Sleep Associates LLC, dba SomnoMedics LLC, and its owner, Edward Killmer Jr. The complaint, filed in U.S. District Court for the Middle District of Florida, alleges that the defendants violated the FCA by knowingly submitting, or causing to be submitted, to the United States false claims for payments from multiple federal health care programs. 

Novo Nordisk, Inc. has entered into a civil settlement agreement with the federal government in which it has agreed to pay the U.S. and several states $1.725 million to resolve allegations that the company caused false or fraudulent claims to be submitted to the Medicaid program in connection with its marketing of the diabetes drugs Novolin, Novolin 70/30, Novolog, and Novolog 70/30.